Humanigen Isn’t Throwing In The Towel On Lenzilumab For COVID-19 Just Yet
The company is assessing a potential path forward in COVID-19 for the drug and is in talks with platform study groups after a Phase III study did not show statistical significance, but still showed activity.
You may also be interested in...
InflaRx Looks Ahead To Late 2023 Commercial Sales For COVID-19 Antibody
The price will be more expensive than prior COVID-19 antibodies, reflecting its target to critically ill patients who are hospitalized.
Otilimab Failure Is A Blow For GSK’s Pipeline, With More Tests To Come
GSK is abandoning one of its new drug prospects after it failed in hard-to-treat rheumatoid arthritis patients at Phase III, raising the stakes for more key readouts due shortly.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: setback for a COVID-19 candidate; Chinese biotechs move into mRNA; Sanofi’s strategic moves into hemophilia; Orion’s deal for its novel prostate cancer candidate; and Roche’s evolving approach to platform deals.